SCHEMBL16009262

SCHEMBL16009262

O=C(O)Cn1ccc(-c2ccccc2F)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
PARP1 P09874 1/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MAPT P10636 2/20 0.39
BRD4 O60885 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
CTSA P10619 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5206196 0.79 KMT2A (0.48) KMT2APOLBMAPTKDM4CHDAC3
SCHEMBL25381974 0.78 EPHB4 (0.50) KMT2AHDAC3HDAC4HDAC1HDAC7
Methane SCHEMBL11623540 0.78 KMT2A (0.47) KMT2APOLBMAPTKDM4CHDAC3
SCHEMBL26112133 0.78 ACSS2 (0.47) KMT2APOLBBRD4ADORA3ADORA2A
Ethane SCHEMBL11626038 0.76 KMT2A (0.50) KMT2APOLBMAPTKDM4CHDAC3
Propane SCHEMBL11622678 0.75 KMT2A (0.49) KMT2AKDM4CHDAC3HDAC4HDAC1
SCHEMBL5650249 0.72 IDO1 (0.42) POLBPARP1MAPTADORA3ADORA2A
SCHEMBL16045671 0.72 PDK2 (0.58) KMT2A
SCHEMBL2277762 0.70 KMT2A (0.53) KMT2APARP1
SCHEMBL31128114 0.70 KMT2A (0.53) KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970285-B1 FUSED TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2019-04-17 EP disclosed
US-20190008866-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2019-01-10 US disclosed
EP-3089970-B1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
US-10085985-B2 Bromodomain inhibitors ABBVIE INC. (US) 2018-10-02 US disclosed
US-20160331749-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2016-11-17 US disclosed
EP-3089970-A1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-11-09 EP disclosed
CN-105939996-A Dihydropyridone and dihydropyridazinone derivatives as bromodomain inhibitors 艾伯维公司 2016-09-14 CN disclosed
US-9428514-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-08-30 US disclosed
EP-2970285-A1 FUSED TETRACYCLIC BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-01-20 EP disclosed
CN-105189504-A Fused tetracyclic bromodomain inhibitors ABBVIE INC 2015-12-23 CN disclosed
WO-2015089075-A1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2015-06-18 WO disclosed
US-20150158873-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2015-06-11 US disclosed
US-20150150884-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2015-06-04 US disclosed
US-8980879-B2 Bromodomain inhibitors ABBVIE INC. (US) 2015-03-17 US disclosed
WO-2014164780-A1 FUSED TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-10-09 WO disclosed
US-20140256710-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150884-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 KMT2A 350/4885POLB 910/4885PARP1 98/4885
US-10085985-B2 Bromodomain inhibitors BRD4, BRD3, BRD1 KMT2A 383/4885POLB 840/4885PARP1 87/4885
US-20190008866-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 KMT2A 383/4885POLB 840/4885PARP1 87/4885
US-20160331749-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 KMT2A 383/4885POLB 840/4885PARP1 87/4885
US-20140256710-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 KMT2A 350/4885POLB 910/4885PARP1 98/4885
US-20150158873-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 KMT2A 383/4885POLB 840/4885PARP1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.